5-Fluor-1-(tetrahydro-2-furyl)uracil
Tegafur
Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
Grundinformationen
- CAS
17902-23-7- Standard-SMILES
O=c1[nH]c(=O)n(C2CCCO2)cc1F- InChIKey
WFWLQNSHRPWKFK-UHFFFAOYSA-N- Summenformel
- C8H9FN2O3
- Durchschnittliche Molmasse
- 200,17 g/mol
- Monoisotopische Masse
- 200,05972037
Überblick
Tegafur is an organohalogen compound and a member of pyrimidines.
Namen und Bezeichner
- Bevorzugter Name
- Tegafur
- IUPAC
- 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione
- Lokaler Name
- 5-Fluor-1-(tetrahydro-2-furyl)uracil
- Englischer Name
- Tegafur
- Summenformel
- C8H9FN2O3
- Molmasse
- 200.17
Namen und Synonyme
tegafur17902-23-7FtorafurFutrafulSinoflurolFentalNeberkCitofurLamarLifrilCoparoginFurafluor
Weitere Namen anzeigen
1-(Tetrahydro-2-furanyl)-5-fluorouracilafurFluaid
FurofutranNitobanilExonalFulfeelTefsiel CRiolFlorafurFT-207
Datenbank-Bezeichner
- CAS
17902-23-7、37076-68-9、82294-77-7- PubChem CID
- 5386
- DTXSID
DTXSID001009966- ChEMBL
CHEMBL20883- ChEBI
CHEBI:32188- UNII
- 1548R74NSZ
- EC Number
- 241-846-2
- Nikkaji
- J4.543H
Eigenschaften
Berechnete StruktureigenschaftenWird ergänzt
- XLogP
- -0,3
- Polarare Oberfläche (TPSA)
- 58,6 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 4
- Frei drehbare Bindungen
- 1
- Schwere Atome
- 14
- Formalladung
- 0
- Komplexität
- 316
Experimentelle und physikochemische Eigenschaften
DrugsPharmaceuticals -> Antineoplastic and immunomodulating agents -> Antineoplastic agents
LogP-0.27
Solubility
Partly miscible
29.9 [ug/mL] (The mean of the results at pH 7.4)
Melting Point339.8-343.4
Physikochemische Eigenschaften
- Schmelzpunkt
- 171 · 171-173 °C(lit.)
- Dichte
- 1.3222 · 1.3222 (estimate)
- storage temp.
- room temp
- Löslichkeit
- 50 mg/mL · DMSO: >50mg/mL
- Aggregatzustand
- Very Fine Crystalline Powder
- pka
- 7.63 · 7.63±0.10(Predicted)
- Farbe
- white to off-white
- Merck
- 14 · 14,9112
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Danger
H301 (95.1%): Toxic if swallowed [Danger Acute toxicity, oral]
P261, P262, P264, P270, P271, P280, P301+P316, P302+P352, P304+P340, P316, P321, P330, P361+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 41 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Other Safety InformationIMAP assessments - 2,4(1H,3H)-Pyrimidinedione, 5-fluoro-1-(tetrahydro-2-furanyl)-: Environment tier I assessment
Hazard Classes and CategoriesAcute Tox. 3 (95.1%)
Sicherheitsdaten
- wgk
- 3
- tsca
- TSCA listed
- ridadr
- UN 2811 6.1/PG 2
- hs_code
- 29349990
- RTECS-Nr.
- YR0450000
- risk_code
- 23/24/25
- Toxizität
- LD50 in mice (mg/kg): 900 orally (3 days) (Yasumoto); 750 i.p. (FR 1574684), also reported as 1150 i.p. (Smart)
- hazard_code
- T
- safety_code
- 22-36/37/39-45
- hazard_class
- 6.1
- packing_group
- II
- Speicherklasse
- 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Chemie und Industrie
Pharmakologische Informationen
ATC Code
L01BC53
L - Antineoplastic and immunomodulating agents
QL - Antineoplastic and immunomodulating agents
Protein BindingTegafur is 52.3% bound to serum proteins and 5-FU is 18.4% protein bound.
Pharmacodynamics
Tegafur is an antineoplastic agent that belongs in the class of pyrimidine analogues. It interferes with the 2'-deoxythymidylate (DTMP) synthesis in the pyrimidine pathway, resulting in inhibition of DNA synthesis. In a phase III trial investigating the clinical efficacy of S-1 (tegafur/gimeracil/oteracil) in patients with advanced or recurrent gastric cancer, treatment resulted in a high response rate and was associated with a longer overall survival and longer progression-free survival rate when used in combination with cisplatin. In a meta analysis, triple combination therapy consisting of tegafur, gimeracil and oteracil showed longer survival times and well tolerance in patients with advanced gastric cancer. Tegafur and its active metabolites are potent myleosuppressive agents.
Mechanism of Action
The transformation of 2'-deoxyurindylate (dUMP) to 2'-deoxythymidylate (dTMP) is essential in driving the synthesis of DNA and purines in cells. Thymidylate synthase catalyzes the conversion of dUMP to dTMP, which is a precursor of thymidine triphosphate (TTP), one of the four deoxyribonucleotides required for DNA synthesis. After administration into the body, tegafur is converted into the active antineoplastic metabolite, fluorouracil (5-FU). In tumour cells, 5-FU undergoes phosphorylation to form the active anabolites, including 5-fluorodeoxyuridine monophosphate (FdUMP). FdUMP and reduced folate are bound to thymidylate synthase leading to formation of a ternary complex which inhibits DNA synthesis. In addition, 5-fluorouridine-triphosphate (FUTP) is incorporated into RNA causing disruption of RNA functions.
Biological Half-LifeThe elimination half life of tegafur is approximately 11 hours.
Metabolism/Metabolites
Zugehörige Reaktionen
50
Notizen zur Verbindung
Wird geladen…